Perosphere Technologies and CoRRect Medical Sign Distribution Agreement for Point-of-Care Coagulometer in Germany
July 25 2024 - 2:00AM
Business Wire
Agreement Brings Perosphere’s Novel Coagulation
Diagnostic Instrument to Second Market in Europe
Perosphere (Perosphere Technologies Inc.), a private medical
technologies company focused on developing next-generation
coagulation diagnostics, today announced that it has signed an
agreement with CoRRect Medical GmbH, a leading medical device
distributor, for the exclusive distribution of Perosphere’s
Point-of-Care (PoC) Coagulometer in Germany.
With this agreement, Perosphere’s PoC Coagulometer will become
available for the first time to hospitals and healthcare
professionals in Germany, where annual anticoagulant prescription
rates per 100,000 persons increased by 135.8% between 2005 and
2016.1 The PoC Coagulometer is a novel pharmacodynamic,
reagent-free diagnostic instrument for use at the point of care,
i.e., bedside to deliver rapid diagnosis of coagulation status and
direct informed treatment decision-making in hospital settings and
outpatient clinics supporting medical management of patients on
anticoagulant therapies, including the Direct Oral Anticoagulants
(DOACs).
“We are eager to partner with CoRRect Medical to introduce
Perosphere’s PoC Coagulometer in Germany, addressing the unmet
medical need in coagulation testing and management to help improve
patient outcomes and reduce associated costs,” said Daryl Mootoo,
Chief Operating Officer of Perosphere. “CoRRect Medical has
outstanding expertise in understanding the needs of healthcare
professionals to provide solutions that can integrate seamlessly
into practice.”
CoRRect Medical specializes in the commercialization and
distribution of high-quality and innovative medical devices for
cardiology, vascular surgery, and cardiac surgery in Germany and
across Europe. CoRRect Medical operates under Uniphar Medtech, a
European medical device distributor with a presence across 21
markets. Within the Uniphar Medtech family of businesses,
Perosphere also has an exclusive agreement with M3 Medical for the
distribution of the PoC Coagulometer in Ireland.
“We are inspired by Perosphere’s medical innovation and proud to
be entrusted as its exclusive partner to bring this point-of-care,
DOAC-sensitive coagulation testing device to the health system in
Germany,” said Michael Braun, Chief Executive Officer of CoRRect
Medical. Mr. Braun added, “The PoC Coagulometer will fill a
critical diagnostic void for healthcare professionals and help
improve care outcomes for patients.”
About Perosphere Technologies Perosphere Technologies is
changing the way decisions are made at the point-of-care in
hospitals and outpatient clinics for patients at risk for bleeding.
A private medical technologies company, Perosphere is focused on
development and commercialization of the novel PoC (point-of-care)
Coagulometer, which quickly informs diagnosis, treatment, and
prevention decisions through precision data, made immediately
accessible to all. It is the only PoC diagnostic instrument that
effectively and swiftly tests clotting times across drug classes,
including the Direct Oral Anticoagulants (DOACs). The PoC
Coagulometer serves to help establish a new standard of care for
patients on anticoagulant therapies or at risk for bleeding, and
has the potential to improve efficiency, provide significant cost
savings, and support better patient outcomes.
The PoC Coagulometer has a CE Mark in the European Union and
is not FDA-cleared in the United States.
For further information, contact us at info@perospheretech.com
or +1 (475) 218-4600.
www.perospheretech.com
About CoRRect Medical GmbH CoRRect Medical GmbH
specializes in the commercialization and distribution of
high-quality and innovative medical devices for cardiology,
vascular surgery and cardiac surgery using minimally invasive
procedures. CoRRect Medical GmbH’s commitment to innovative
technologies brings medical progress to patients, saving their
lives and increasing their quality of life. Our aim is to find new
products which help patients in case of illness and offer treating
physicians procedural optimization. The CoRRect Medical team has
been introducing new innovative technologies into Germany,
Switzerland and the EU over the last 30 years. For more
information, visit https://correctmedical.com/en/home-en/.
1 Guelker, J. et al. Increasing use of anticoagulants in Germany
and its impact on hospitalization for gastrointestinal bleeding.
Thrombosis Research, 181, 2019, 135-140.
https://doi.org/10.1016/j.thromres.2019.07.009.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240724129537/en/
MEDIA Ellie Hanson FINN Partners
ellie.hanson@finnpartners.com +972 2 589 2006